News

Latest News

Desktop and Tablet

Life Sciences Review Magazine Features Andira as Cover Story

Life Sciences Review has awarded Andira Pharmaceuticals the Top Therapeutic & Medical Device Products Provider 2023, and feature Andira in the August 17, 2023 issue with CEO, Dana Lambert, PhD on the cover. The article written by Jeremy Williams, begins, “The healthcare sector eagerly anticipates the next chapter of innovation

Read more
metastatic cancer drug development

Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer

Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British

Read more
Janette Lyons, CFO for Andira

Janette Lyons Joins Andira Pharmaceuticals as CFO

Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience.  She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,

Read more
Drip cannabinoid antibiotic

Andira Pharmaceuticals Hires Eurofins Discovery to Further Develop Lead Asset

VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success

Read more

Andira Welcomes Ryan Miller to Advisory Board

Vancouver, BC –  Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his

Read more

Two Mitacs Grants Awarded for Anti-Infective Wound Care R&D

Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,

Read more

Andira Pharmaceuticals Secures Exclusive Worldwide License for Cannabinoid Antibiotics and Drug Delivery Systems

Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors

Read more

Mobile Only

Life Sciences Review Magazine Features Andira as Cover Story

Life Sciences Review has awarded Andira Pharmaceuticals the Top Therapeutic & Medical Device Products Provider 2023, and feature Andira in the August 17, 2023 issue with CEO, Dana Lambert, PhD on the cover. The article written by Jeremy Williams, begins, “The healthcare sector eagerly anticipates the next chapter of innovation

Read more
metastatic cancer drug development

Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer

Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British

Read more
Janette Lyons, CFO for Andira

Janette Lyons Joins Andira Pharmaceuticals as CFO

Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience.  She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,

Read more
Drip cannabinoid antibiotic

Andira Pharmaceuticals Hires Eurofins Discovery to Further Develop Lead Asset

VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success

Read more

Andira Welcomes Ryan Miller to Advisory Board

Vancouver, BC –  Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his

Read more

Two Mitacs Grants Awarded for Anti-Infective Wound Care R&D

Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,

Read more

Andira Pharmaceuticals Secures Exclusive Worldwide License for Cannabinoid Antibiotics and Drug Delivery Systems

Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors

Read more